[{"id":"b0107240-c9ff-4b67-b853-211b0d9cdc8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469774","created_at":"2026-03-28T01:44:13.768Z","updated_at":"2026-03-28T01:44:13.768Z","phase":"Phase 1/2","brief_title":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07469774","lead_sponsor":"Biocity Biopharmaceutics Co., Ltd.","biomarkers":" EGFR • BRAF • ALK • MET • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • ALK • MET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/17/2026","start_date":" 03/17/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2026-03-13"},{"id":"7bf97edf-e25d-4101-b19d-5329b59d36b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT07204340","created_at":"2025-10-04T08:02:21.190Z","updated_at":"2025-10-04T08:02:21.190Z","phase":"Phase 1","brief_title":"TLN-372 in Advanced KRAS Mutant Solid Tumors","source_id_and_acronym":"NCT07204340","lead_sponsor":"Treeline Biosciences, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 10/09/2025","start_date":" 10/09/2025","primary_txt":" Primary completion: 12/03/2031","primary_completion_date":" 12/03/2031","study_txt":" Completion: 04/01/2032","study_completion_date":" 04/01/2032","last_update_posted":"2025-10-02"},{"id":"ab44ad05-9bd9-4db7-9ebb-ab1b8496e06f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190027","created_at":"2025-09-27T08:39:53.097Z","updated_at":"2025-09-27T08:39:53.097Z","phase":"Phase 1/2","brief_title":"Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","source_id_and_acronym":"NCT07190027","lead_sponsor":"First Affiliated Hospital of Wenzhou Medical University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 246","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2025-09-24"},{"id":"b11c3dd5-a7d2-45b9-88bd-188586703589","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190248","created_at":"2025-09-27T08:39:58.068Z","updated_at":"2025-09-27T08:39:58.068Z","phase":"Phase 3","brief_title":"A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","source_id_and_acronym":"NCT07190248","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1 • KRAS","pipe":"","alterations":" ","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • calderasib (MK-1084)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 10/27/2025","start_date":" 10/27/2025","primary_txt":" Primary completion: 12/07/2029","primary_completion_date":" 12/07/2029","study_txt":" Completion: 08/06/2032","study_completion_date":" 08/06/2032","last_update_posted":"2025-09-24"},{"id":"a3f2cdb8-5f51-4d49-bdd8-408b76b63c70","acronym":"ZANGEA","url":"https://clinicaltrials.gov/study/NCT07176312","created_at":"2025-09-20T07:08:39.876Z","updated_at":"2025-09-20T07:08:39.876Z","phase":"Phase 2","brief_title":"Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients","source_id_and_acronym":"NCT07176312 - ZANGEA","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • Ziihera (zanidatamab-hrii)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-09-16"},{"id":"6327dec6-05f5-4a23-9177-c88c3db8f2ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT06951399","created_at":"2025-07-26T13:31:06.459Z","updated_at":"2025-07-26T13:31:06.459Z","phase":"Phase 2","brief_title":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06951399","lead_sponsor":"Rabin Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2025-07-22"},{"id":"78b1d8da-ee62-4e5e-a188-4a012d565c96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06863402","created_at":"2025-07-19T13:20:16.362Z","updated_at":"2025-07-19T13:20:16.362Z","phase":"Phase 2","brief_title":"Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype","source_id_and_acronym":"NCT06863402","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • nemtabrutinib (MK-1026)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/01/2029","primary_completion_date":" 04/01/2029","study_txt":" Completion: 04/01/2030","study_completion_date":" 04/01/2030","last_update_posted":"2025-07-18"},{"id":"f13e82aa-caf5-4f36-9021-170e80729eb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT07061977","created_at":"2025-07-19T14:14:48.551Z","updated_at":"2025-07-19T14:14:48.551Z","phase":"Phase 3","brief_title":"Induction Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","source_id_and_acronym":"NCT07061977","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 336","initiation":"Initiation: 09/19/2025","start_date":" 09/19/2025","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-07-14"},{"id":"cef8e42f-da33-450a-942c-ff0f7c445fa9","acronym":"PlugIN","url":"https://clinicaltrials.gov/study/NCT06906822","created_at":"2025-06-28T13:38:14.863Z","updated_at":"2025-06-28T13:38:14.863Z","phase":"Phase 2","brief_title":"PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients","source_id_and_acronym":"NCT06906822 - PlugIN","lead_sponsor":"Grupo Español Multidisciplinar de Melanoma","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-06-27"},{"id":"7152824f-51d6-434a-a17c-b34a21be5fde","acronym":"","url":"https://clinicaltrials.gov/study/NCT07037004","created_at":"2025-06-28T13:42:45.741Z","updated_at":"2025-06-28T13:42:45.741Z","phase":"Phase 2","brief_title":"Adding a Probiotic (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery","source_id_and_acronym":"NCT07037004","lead_sponsor":"City of Hope Medical Center","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 05/04/2026","start_date":" 05/04/2026","primary_txt":" Primary completion: 05/04/2027","primary_completion_date":" 05/04/2027","study_txt":" Completion: 05/04/2027","study_completion_date":" 05/04/2027","last_update_posted":"2025-06-25"},{"id":"8260f352-f0e1-4ec2-80e3-a705d1b2d6be","acronym":"","url":"https://clinicaltrials.gov/study/NCT06980272","created_at":"2025-06-28T13:43:54.833Z","updated_at":"2025-06-28T13:43:54.833Z","phase":"Phase 3","brief_title":"SSGJ-707 in Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06980272","lead_sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 06/20/2025","start_date":" 06/20/2025","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-06-24"},{"id":"38ae3e19-8dad-4b01-a570-b25b5bcb525a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06919666","created_at":"2025-06-21T13:16:45.845Z","updated_at":"2025-06-21T13:16:45.845Z","phase":"Phase 1/2","brief_title":"NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06919666","lead_sponsor":"University of Colorado, Denver","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • NT219"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 02/01/2030","primary_completion_date":" 02/01/2030","study_txt":" Completion: 02/01/2031","study_completion_date":" 02/01/2031","last_update_posted":"2025-06-18"},{"id":"c6f24729-d5a7-4244-ad7f-a2cffb7113b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06917079","created_at":"2025-06-07T14:12:37.863Z","updated_at":"2025-06-07T14:12:37.863Z","phase":"Phase 1","brief_title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","source_id_and_acronym":"NCT06917079","lead_sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 287","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2025-06-06"},{"id":"ff1be9d1-13a5-4b53-8202-0376c103961f","acronym":"SUNRAY-02","url":"https://clinicaltrials.gov/study/NCT06890598","created_at":"2025-06-07T14:38:17.196Z","updated_at":"2025-06-07T14:38:17.196Z","phase":"Phase 3","brief_title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06890598 - SUNRAY-02","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imfinzi (durvalumab) • olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 03/27/2025","start_date":" 03/27/2025","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 02/01/2032","study_completion_date":" 02/01/2032","last_update_posted":"2025-06-05"},{"id":"5de3ae22-f200-40ed-bea2-6427c55b3ad9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06984328","created_at":"2025-06-07T14:42:38.975Z","updated_at":"2025-06-07T14:42:38.975Z","phase":"Phase 2","brief_title":"Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)","source_id_and_acronym":"NCT06984328","lead_sponsor":"Genmab","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • acasunlimab (GEN1046)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 07/15/2027","primary_completion_date":" 07/15/2027","study_txt":" Completion: 07/15/2029","study_completion_date":" 07/15/2029","last_update_posted":"2025-06-03"},{"id":"1f0aec53-2934-4132-a061-58ff65518298","acronym":"","url":"https://clinicaltrials.gov/study/NCT06984588","created_at":"2025-09-07T01:41:15.296Z","updated_at":"2025-09-07T01:41:15.296Z","phase":"Phase 2/3","brief_title":"A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06984588","lead_sponsor":"TJ Biopharma Co., Ltd.","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Loqtorzi (toripalimab-tpzi) • uliledlimab (TJD5)"],"overall_status":"Recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 03/28/2024","start_date":" 03/28/2024","primary_txt":" Primary completion: 08/05/2028","primary_completion_date":" 08/05/2028","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-05-22"},{"id":"008c4fb4-f4aa-40c4-a175-3806ddd34919","acronym":"ARTEMIDELung04","url":"https://clinicaltrials.gov/study/NCT06868277","created_at":"2025-06-07T15:03:08.757Z","updated_at":"2025-06-07T15:03:08.757Z","phase":"Phase 3","brief_title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT06868277 - ARTEMIDELung04","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 830","initiation":"Initiation: 04/10/2025","start_date":" 04/10/2025","primary_txt":" Primary completion: 01/17/2030","primary_completion_date":" 01/17/2030","study_txt":" Completion: 12/02/2030","study_completion_date":" 12/02/2030","last_update_posted":"2025-05-14"},{"id":"297cd590-bacb-40d9-b395-eacfa8bc49d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06949761","created_at":"2025-09-07T01:25:54.516Z","updated_at":"2025-09-07T01:25:54.516Z","phase":"Phase 1/2","brief_title":"A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","source_id_and_acronym":"NCT06949761","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • Qibeian (iparomlimab/tuvonralimab) • QL1203"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-04-29"},{"id":"cab8053f-6a2a-419a-97ce-e6c8bbd0a512","acronym":"NeoCARD","url":"https://clinicaltrials.gov/study/NCT06845319","created_at":"2025-02-27T07:07:22.165Z","updated_at":"2025-02-27T07:07:22.165Z","phase":"Phase 2","brief_title":"Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT06845319 - NeoCARD","lead_sponsor":"Medical University of South Carolina","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-02-25"},{"id":"0d632197-009b-4cc8-8b15-f154cec2fe79","acronym":"ACCIO","url":"https://clinicaltrials.gov/study/NCT04267848","created_at":"2021-01-18T20:44:14.334Z","updated_at":"2025-02-25T12:37:33.994Z","phase":"Phase 3","brief_title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial","source_id_and_acronym":"NCT04267848 - ACCIO","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • Pembroria (pembrolizumab biosimilar) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 1210","initiation":"Initiation: 06/16/2020","start_date":" 06/16/2020","primary_txt":" Primary completion: 12/15/2025","primary_completion_date":" 12/15/2025","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2025-02-24"},{"id":"1394e99e-c38f-44e4-ab4d-aee1d10301bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05507541","created_at":"2022-08-19T17:10:01.039Z","updated_at":"2025-02-25T12:28:56.881Z","phase":"Phase 2","brief_title":"TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT05507541","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • ALK • BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" ALK positive","tags":["PD-L1 • ALK • BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-24"},{"id":"3c07681e-1c58-4557-8010-1fc74e4cbe8d","acronym":"KRYSTAL-7","url":"https://clinicaltrials.gov/study/NCT04613596","created_at":"2021-01-19T20:33:04.646Z","updated_at":"2025-02-25T12:27:47.978Z","phase":"Phase 2/3","brief_title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","source_id_and_acronym":"NCT04613596 - KRYSTAL-7","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 806","initiation":"Initiation: 12/02/2020","start_date":" 12/02/2020","primary_txt":" Primary completion: 10/31/2028","primary_completion_date":" 10/31/2028","study_txt":" Completion: 10/31/2029","study_completion_date":" 10/31/2029","last_update_posted":"2025-02-24"},{"id":"533b1900-f580-4f57-b6fc-c304162a280a","acronym":"MK-1084-004","url":"https://clinicaltrials.gov/study/NCT06345729","created_at":"2024-04-03T14:39:59.477Z","updated_at":"2025-02-25T12:30:27.021Z","phase":"Phase 3","brief_title":"A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)","source_id_and_acronym":"NCT06345729 - MK-1084-004","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • calderasib (MK-1084)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 05/24/2024","start_date":" 05/24/2024","primary_txt":" Primary completion: 02/19/2029","primary_completion_date":" 02/19/2029","study_txt":" Completion: 02/18/2031","study_completion_date":" 02/18/2031","last_update_posted":"2025-02-24"},{"id":"67ef8418-6d77-4d74-95d8-80f63ef20ed4","acronym":"SWOG S2001","url":"https://clinicaltrials.gov/study/NCT04548752","created_at":"2021-01-18T21:45:16.998Z","updated_at":"2025-02-25T12:27:43.236Z","phase":"Phase 2","brief_title":"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations","source_id_and_acronym":"NCT04548752 - SWOG S2001","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 02/22/2021","start_date":" 02/22/2021","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-24"}]